Our laboratory's research interests focus on cell therapy with cytotoxic T cells (CTL) for viral and malignant diseases. Led by Catherine Bollard, MD, we are running clinical trials assessing the safety of adoptively transferred donor-derived virus-specific CTL for the prevention and treatment of viral infection after allogeneic stem cell and cord blood transplant.  In addition, we are investigating the utility of this approach using genetically modified virus-specific CTL for the prevention and treatment of viral infection and relapse after transplant. We also are evaluating the efficacy of tumor-specific CTL in patients with relapsed EBV-positive Hodgkin’s disease and non-Hodgkin Lymphoma.  Further, we are interested in novel strategies to target the cancer stem cell in lymphoma and to counteract tumor immune evasion mechanisms to enhance the efficacy of adoptive immunotherapy protocols. We are also exploring the feasibility of expanding T cells targeting non-EBV tumor-associated antigens to treat EBV-negative lymphomas and leukemias as well as HIV.

Dr. Bollard is also the Director of the Program for Emerging Technologies in Immune Cell Therapies.

Laboratory members:

Representative publications:

Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res 2011;17(22):7058-66. doi: 10.1158/1078-0432.CCR-11-1873. Epub 2011 Sep 9.

Hanley PJ, Shaffer DR, Cruz CR, Ku S, Tzou B, Liu H, Demmler-Harrison G, Heslop HE, Rooney CM, Gottschalk S, Bollard CM. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy 2011;13(8):976-86. doi: 10.3109/14653249.2011.575356. Epub 2011 May 4

Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114(9):1958-67. doi: 10.1182/blood-2009-03-213256. Epub 2009 May 14

Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12(10):1160-6. Epub 2006 Sep 24.

Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004;200(12):1623-33.

Catherine Bollard, MD
Program for Emerging Technologies in Immune Cell Therapies